Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set

Abstract
A number of new treatments have been approved for patients with multiple myeloma (MM) and the survival of patients continues to improve. However, discrepancies in outcomes of clinical trials and th...
Funding Information
  • Takeda
  • National Institute for Health Research University College London Hospitals Biomedical Research Centre